European backing for another PD-L1 antibody with Merck and Pfizer announcing approval of BAVENCIO (avelumab) for the treatment of adult patients with metastatic merkel cell carcinoma.

Biosimilars are not just causing a degree of angst in Australia with Pfizer in the US taking Johnson & Johnson to court over infliximab.

More than four-in-five Australians take at least one medication on a regular basis, according to a survey conducted by the Australian Bureau of Statistics for the Australian Institute of Health and Welfare.

it is understood the reason for not including the WHO option is that the Geneva-based organisation will shortly announce plans to scrap it, leaving countries to go their own way.

Government spending on health would fall by as much as $265 billion over three years if government adopted a proposal from the Liberal Democrats to abolish virtually every federal health program, including the PBS.

PBAC will consider two PCSK9 inhibitor therapies at its November meeting for the treatment of familial hypercholesterolaemia.

Most consider the debate over the naming convention for biologics arcane and esoteric, and few will read this, but it is very important for the sector. PharmaDispatch has tried to capture the history and complexity of a debate that remains unresolved.

The company, which is quickly emerging as one of the leading biosimilar companies, is backing the European naming system over the American unique identifier.

PharmaDispatch has obtained the supporting statements from each of the 16 candidates for the Medicines Australia Board.

October will see the listing of new generics, a new brand to address shortages of an arthritis treatment, and a new a new treatment for schizophrenia.